…is to leverage its interdisciplinary expertise in pharmaceutical product development to identify, develop and market high value new medicines in niche indications, in which there is a significant unmet medical need and where the company can partially or completely drive and participate in the commercialization of the product. Our focuses is on projects that address orphan population needs while also enabling a time and cost-effective path to market. To achieve our objectives, Calliditas intends to pursue the following strategy:
To rapidly and efficiently establish a new standard of care in orphan indications. Upon market approval, Calliditas intends to maximize the potential of its products by commercializing on a standalone basis in the US market and through partnerships in other regions.
To leverage our proprietary formulation expertise and significant experience in drug development to selectively explore treatments in orphan diseases where there is a strong scientific and clinical rationale and attractive commercial opportunities.
To enhance our product portfolio by leveraging the company’s capabilities to identify and in-license additional, mainly late-stage, product candidates with a strong strategic and commercial fit.